靶向脂蛋白(a)的长效小干扰RNA lepodisiran:一项随机剂量递增临床试验
这项在美国和新加坡5个临床研究站点开展的1期随机单次剂量递增试验纳入48名无心血管疾病且脂蛋白(a)≥75 nmol/L的成人,评估lepodisiran的安全性和耐受性。lepodisiran耐受良好,并产生剂量依赖、长效的血清脂蛋白(a)浓度降低,最高剂量组第337天中位降幅达-94%。
要点
- lepodisiran单次皮下给药后血浆浓度10.5小时内达峰,48小时内检测不到。
- 脂蛋白(a)最大中位降幅从4 mg组的-41%递增至608 mg组的-97%。
- 608 mg组第337天脂蛋白(a)中位变化为-94%,显示长效降低作用。
核心结论
- 在这项纳入48名脂蛋白(a)升高参与者的1期研究中,lepodisiran耐受良好,并产生剂量依赖、长效的血清脂蛋白(a)浓度降低;研究结果支持对lepodisiran开展进一步研究。
研究设计与样本
- 单次剂量递增试验,在美国和新加坡5个临床研究站点开展,于2020年11月18日至2021年12月7日纳入48名无心血管疾病且血清脂蛋白(a)≥75 nmol/L(或≥30 mg/dL)的成人,末次随访于2022年11月9日。
- 参与者随机接受安慰剂或单次皮下注射lepodisiran 4 mg、12 mg、32 mg、96 mg、304 mg或608 mg。
- 主要结局为单次剂量递增lepodisiran的安全性和耐受性;次要结局包括给药后168天血浆lepodisiran水平及最长随访336天(48周)空腹血清脂蛋白(a)浓度变化。
主要发现
- 48名参与者平均年龄46.8岁(SD 11.6),女性占35%,发生1例严重不良事件。
- lepodisiran血浆浓度在10.5小时内达峰,48小时内检测不到。
- 脂蛋白(a)最大中位变化:安慰剂组-5%(IQR -16%至11%),4 mg组-41%(IQR -47%至-20%),12 mg组-59%(IQR -66%至-53%),32 mg组-76%(IQR -76%至-75%),96 mg组-90%(IQR -94%至-85%),304 mg组-96%(IQR -98%至-95%),608 mg组-97%(IQR -98%至-96%)。
- 第337天时,608 mg组脂蛋白(a)中位变化为-94%(IQR -94%至-85%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Epidemiological and genetic data have implicated lipoprotein(a) as a potentially modifiable risk factor for atherosclerotic disease and aortic stenosis, but there are no approved pharmacological treatments. OBJECTIVES: To assess the safety, tolerability, pharmacokinetics, and effects of lepodisiran on lipoprotein(a) concentrations after single doses of the drug; lepodisiran is a short interfering RNA directed at hepatic synthesis of apolipoprotein(a), an essential component necessary for assembly of lipoprotein(a) particles. DESIGN, SETTING, AND PARTICIPANTS: A single ascending-dose trial conducted at 5 clinical research sites in the US and Singapore that enrolled 48 adults without cardiovascular disease and with lipoprotein(a) serum concentrations of 75 nmol/L or greater (or ≥30 mg/dL) between November 18, 2020, and December 7, 2021; the last follow-up visit occurred on November 9, 2022. INTERVENTIONS: Participants were randomized to receive placebo or a single dose of lepodisiran (4 mg, 12 mg, 32 mg, 96 mg, 304 mg, or 608 mg) administered subcutaneously. MAIN OUTCOMES AND MEASURES: The primary outcome was the safety and tolerability of the single ascending doses of lepodisiran. The secondary outcomes included plasma levels of lepodisiran for 168 days after dose administration and changes in fasting lipoprotein(a) serum concentrations through a maximum follow-up of 336 days (48 weeks). RESULTS: Of the 48 participants enrolled (mean age, 46.8 [SD, 11.6] years; 35% were women), 1 serious adverse event occurred. The plasma concentrations of lepodisiran reached peak levels within 10.5 hours and were undetectable by 48 hours. The median baseline lipoprotein(a) concentration was 111 nmol/L (IQR, 78 to 134 nmol/L) in the placebo group, 78 nmol/L (IQR, 50 to 152 nmol/L) in the 4 mg of lepodisiran group, 97 nmol/L (IQR, 86 to 107 nmol/L) in the 12-mg dose group, 120 nmol/L (IQR, 110 to 188 nmol/L) in the 32-mg dose group, 167 nmol/L (IQR, 124 to 189 nmol/L) in the 96-mg dose group, 96 nmol/L (IQR, 72 to 132 nmol/L) in the 304-mg dose group, and 130 nmol/L (IQR, 87 to 151 nmol/L) in the 608-mg dose group. The maximal median change in lipoprotein(a) concentration was -5% (IQR, -16% to 11%) in the placebo group, -41% (IQR, -47% to -20%) in the 4 mg of lepodisiran group, -59% (IQR, -66% to -53%) in the 12-mg dose group, -76% (IQR, -76% to -75%) in the 32-mg dose group, -90% (IQR, -94% to -85%) in the 96-mg dose group, -96% (IQR, -98% to -95%) in the 304-mg dose group, and -97% (IQR, -98% to -96%) in the 608-mg dose group. At day 337, the median change in lipoprotein(a) concentration was -94% (IQR, -94% to -85%) in the 608 mg of lepodisiran group. CONCLUSIONS AND RELEVANCE: In this phase 1 study of 48 participants with elevated lipoprotein(a) levels, lepodisiran was well tolerated and produced dose-dependent, long-duration reductions in serum lipoprotein(a) concentrations. The findings support further study of lepodisiran. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04914546.
引用
- Nissen SE, Linnebjerg H, Shen X, et al. Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial. JAMA. 2023. PMID: 37952254. doi:10.1001/jama.2023.21835
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。